AYVAKIT (avapritinib)

SELF-ADMINISTRATION

Indications for Prior Authorization:
  • Indicated for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations
Patients must meet the following criteria for the indication(s) above:
  • 18 years of age or older, AND
  • Prescribed by an oncologist, AND
  • Patient has a diagnosis of unresectable or metastatic GIST, AND
  • Patient has a PDGFRA exon 18 mutation, including PDGFRA D842V mutations, as confirmed by chart note documentation, AND
  • Patient has tried and failed Imatinib, AND
  • Coadministration of Ayvakit™ with strong and moderate CYP3A inhibitors or inducers should be avoided
Dosing:
  • 300 mg orally once daily until disease progression or unacceptable toxicity
  • If concomitant use with a moderate CYP3A inhibitor cannot be avoided, reduce the starting dose of Ayvakit™ from 300 mg orally once daily to 100 mg orally once daily
Approval:
  • 1 year

 

Last review date: May 19, 2020

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone